Navigation Links
Gene Therapy Overcomes Heart Failure In Muscular Dystrophy

Researchers at the University of Pittsburgh have successfully treated heart failure in an animal model that is genetically //prone to develop a human muscular dystrophy. The article detailing this study is published in the Oct. 25 edition of the journal Circulation. The authors say that this is the first time that a gene therapy has been used in a therapeutic way.

Lead author, Xiao Xiao, Ph.D., associate professor of orthopedic surgery at the University of Pittsburgh School of Medicine said that attempts to treat the muscle with genes directed at it have been successful because of inherent characteristics of the muscle itself, 'Previous attempts at systemic gene therapy for muscle have not been very effective because blood vessel capillaries act much like a mosquito net, blocking the gene drugs from reaching the muscle cells. Fortunately, we found a virus that is just small and sneaky enough to get through this net and deliver the therapeutic gene to both skeletal and cardiac muscle cells,' he said.

The virus that was successfully used to deliver the gene to the muscle is named the adeno-associated virus, or AAV, a class of relatively small viruses that do not cause any known disease. Dr Xiao and his team used the AAV-8, which can penetrate the capillary net and thus can be effective in whole body treatments. The team tested this therapy against limb girdle muscular dystrophy, or LGMD. In humans, this condition leads to severe damage and weakness to muscles, particularly around the hips and shoulders and the heart. Naturally, the lifespan is shortened owing to cardiac and respiratory failure. The injection of a high dose of AAV-8 was accompanied by significant improvements in the skeletal and cardiac muscle tones in the affected hamsters. After eight months of gene therapy, the hamsters were found to have completely normal hearts. The untreated LGMD animals died of heart failure or other complications of muscular dystrophy by 37 weeks, while the t reated animals survived beyond the study period of 48 weeks. 'When we began the experiment, we anticipated that the treatment would be effective. However, we never imagined it would be so effective, particularly in protecting against or reversing the damage to the heart caused by this mutation and extending lifespan,' concluded Dr. Tong Zhu, M.D., Ph.D., a research associate in the department of orthopedic surgery and the first author of the study. 'In fact, if this study holds up in human clinical trials, it may have profound implications for the treatment of heart failure.'


'"/>




Related medicine news :

1. Cancer Doctors Okays Controversial Prostate Therapy
2. Consensus on "Combination Therapy" for Breast Cancer
3. Gene Therapy shows promise in treating Hemophilia
4. "Make AIDS Therapy affordable" - Physicians demand
5. Hormone replacement Therapy a headache
6. Simple Therapy
7. Therapy for stopping the spread of cancer cells
8. Gene Therapy Destroys Pancreatic Cancer Cells
9. Letrozole Beats Tamoxifen in Breast Cancer Therapy
10. Garlic Supplements Impede HIV Therapy
11. Gene Therapy For Cystic Fibrosis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/22/2017)... ... 2017 , ... Vighter, a premier provider of Unconventional Medical ... PSC.1-2012. The company’s work in countries throughout Southwest Asia, South America, and the ... degraded. The PSC.1 standard was created to protect fundamental freedoms and human rights ...
(Date:6/20/2017)... (PRWEB) , ... June 20, 2017 , ... ... services, announced today that Claritas Capital, a Nashville-based private equity firm, has invested ... our expansion plans for some time, and Claritas Capital offers the smart money, ...
(Date:6/20/2017)... ... June 20, 2017 , ... After months of negotiations, FaceCradle USA is proud to ... on Wednesday, June 21. , “Introducing our product on QVC is something we all worked ... our travel pillow to more than 90 million homes in the United States,” said FaceCradle ...
(Date:6/20/2017)... , ... June 20, 2017 , ... Fresenius Vascular Care, ... minimally invasive techniques to treat and manage a wide range of vascular conditions, has ... initiative. With more than 65 centers represented by more than 40 local brands, a ...
(Date:6/20/2017)... ... June 20, 2017 , ... HOUSTON – Brazos Towers at Bayou Manor ... of new options for today’s modern senior. Brazos Towers at Bayou Manor has more ... love while offering them the services to support that lifestyle both now and in ...
Breaking Medicine News(10 mins):
(Date:6/12/2017)... , June 12, 2017 Kineta, Inc., a biotechnology ... Kineta Vice President of R&D and Head of ... Pandemic Preparedness for the Northwest and Beyond meeting ... on June 14, 2017 from 8:30-10:30 AM PDT at the ... Dr. Bedard will be joined by other ...
(Date:6/9/2017)... and INDIANAPOLIS , June 9, ... living with diabetes. In a further effort to help ... affected by this condition, the International Diabetes Federation (IDF) ... ) have come together for the second phase of ... Systems programme (BRIDGES 2), reaffirming their commitment to helping ...
(Date:6/7/2017)... -- Endo International plc (NASDAQ: ENDP ) ... Joseph R. Goodwin , U.S. District Court Judge for ... , entered a case management order in MDL 2325, ... Litigation (the "MDL") that includes a provision requiring plaintiffs ... on specific causation within one hundred twenty (120) days ...
Breaking Medicine Technology: